Abstract 953P
Background
Second-line treatment options for patients with unresectable hepatocellular carcinoma (uHCC) are limited. Monotherapy with regorafenib or tislelizumab (an anti-PD-1 antibody) has shown clinical benefit for uHCC in the second-line setting. The present study explored the safety and efficacy of the tislelizumab plus regorafenib as second-line therapy for uHCC.
Methods
This was a single-arm, investigator-initiated phase II trial. Patients with confirmed uHCC were enrolled to receive tislelizumab (200mg, q3w) plus regorafenib (80mg-160mg, daily, 3 weeks on/1 week off, every 4 weeks). The primary endpoint was safety and tolerability; Secondary endpoints included overall response rates (ORR), progression-free survival (PFS), and disease control rate (DCR) per mRECIST.
Results
A total of 28 patients were enrolled with median age of 59 years (range: 40-76) and 96% were men. Most common etiology of HCC was hepatitis B (n=26, 93%). 54% of patients were Barcelona Clinic Liver Cancer stage C. 67.9% of patients received prior treatment with tyrosine kinase inhibitors (TKIs; sorafenib [50%] or lenvatinib [17.9%]), and 21.4% received TKIs plus PD-1 antibody. ORR was 28.6% and DCR was 71.4%, with 3 pts having CR, 5 PR, and 12 SD. At the data cut-off date, the median PFS of the 28 pts was 6.4 months (95%Cl 90%, NA)), and the median OS was not reached. The most common treatment-related adverse events at any grade were rash (6/28;21%), hypertension (9/28;32%), hand-foot syndrome (18/28;64%) and fatigue (7/28;25%), which were mostly grade 1 or 2 in severity.
Conclusions
This study indicated that tislelizumab plus regorafenib is an effective and well-tolerated therapeutic option for patients with uHCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuetao Shi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18